Read metronidazole Results-at-a-Glance summary.
Metronidazole is an antibiotic that is often used when treating infants with complicated intra-abdominal infections. However, the medicine is not approved for use in infants by the U.S. Food and Drug Administration (FDA). This study was needed to learn more about the safest and most effective dosage of metronidazole for treating cIAIs in infants.
Read PPE Results-at-a-Glance summary.
Personal protective equipment (PPE) is worn by health care providers to protect them from exposure to hazardous materials such as chemicals or infectious diseases. Previous studies examining the effects of PPE on health care providers’ ability to perform emergency tasks have had mixed results. Additionally, there have not been studies evaluating the performance of these tasks on children while wearing PPE. These studies were needed to determine how PPE impacts health care providers’ ability to perform emergency care for pediatric groups.
Read the babyTAPE Results-at-a-Glance summary.
There are several existing weight estimation formulas for children, but most are for older children and cannot be applied to infants 0-90 days old. The babyTAPE studies developed a formula and device to fill this gap and accurately estimate the weight of infants.
Read the ampicillin Results-at-a-Glance summary.
Ampicillin, a medicine used to treat infections, is the most commonly used drug in babies born prematurely who are admitted to the hospital. At the same time, practically no one has ever figured out how the drug is processed in newborns. The goal of the “Ampicillin in Infants Study” was to find out how newborns process ampicillin and determine the safest and most effective dose to treat infections.
Read the caffeine citrate Results-at-a-Glance summary.
Almost all infants born at less than 29 weeks gestational age develop apnea of prematurity (AOP). Caffeine citrate is often used in the neonatal intensive care unit (NICU) to treat AOP. However, the drug label for caffeine citrate was last updated by the FDA in 1999. This label recommends short-term use of the drug for premature infants 28 – 33 weeks gestational age, but caffeine citrate is frequently used in
infants born earlier. This study was needed to identify the association of caffeine citrate use and safety in infants less than 29 weeks gestational age and to bridge the gap in caffeine citrate’s label recommendations and current clinical practice.
Read the POP01 Results-at-a-Glance summary.
Many drugs that physicians prescribe to children are understudied and many lack dosing recommendations. This lack of information on pediatric drug dosing and safety can put children at risk for side effects and treatment failure when given a drug therapy that is not dosed appropriately.
Read the meropenem Results-at-a-Glance summary.
Infections in the intestines are common in premature infants younger than three months old. These infections are dangerous, and the infants often die. Meropenem is a medicine used to treat many different kinds of infections. It was approved for use in adults and older children, but until this study no one knew how the medicine affects infants younger than three months old.
Read the lisinopril Results-at-a-Glance summary.
Lisinopril is approved for treating high blood pressure in adults and children over 6 years old. But the best, safest dose of lisinopril in children under age 6 had never been figured out. High blood pressure is common in children and teens who have had a kidney transplant, but no one knew the correct dose for this group either.
Read the acyclovir Results-at-a-Glance summary.
Herpes simplex virus (HSV) is a dangerous infection that can often cause death or mental disability in infants. Acyclovir is a medicine approved by the U.S. Food and Drug Administration (FDA) for HSV but the best and safest dose of acyclovir for infants, particularly premature infants, was not previously known. The “Open-Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants” study was conducted in order to learn more about the appropriate level of acyclovir dosing for infants.
